Fatima Karzai, M.D.
Dr. Karzai is the Clinic Chief and Inpatient Director for the Genitourinary Malignancies Branch. Her clinical research is focused on immunotherapeutic therapies and DNA damage repair pathways. Her interests lie in the field of hormonally driven cancers and clinical trial development, particularly in advanced prostate cancer. Dr. Karzai's work emphasizes novel combination therapies involving immunotherapeutic agents, small molecules, and cytotoxic therapies. Dr. Karzai's mission is to provide patients with novel treatment strategies that harness the power of the immune system.
2) hormonally driven cancers
3) immune checkpoint inhibitors
4) PARP inhibitors
5) DNA damage repair
As Clinic Chief and Inpatient Director for the Genitourinary Malignancies Branch, Dr. Karzai is passionate about patient care and clinical research. Dr. Karzai's research is focused on novel combination therapies in prostate cancer, particularly with immunotherapeutic agents such as immune checkpoint blocking antibodies and agents targeting defects in DNA damage repair pathways. The Genitourinary Malignancies Branch enrolls patients onto clinical trials in all stages of prostate cancer.
Selected Key Publications
A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer.BJU Int. 116(4): 546-555, 2015. [ Journal Article ]
Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma.Clin Genitourin Cancer. 15(1): 77-85, 2017. [ Journal Article ]
- Future Oncol. 12(16): 1947-1955, 2016. [ Journal Article ]
Dr. Karzai received her M.D. from The George Washington University School of Medicine and Health Sciences in Washington, DC where she also completed her Internal Medicine residency. She completed her fellowship in Medical Oncology and Hematology at the National Cancer Institute (NCI) and the National Heart, Lung, and Blood Institute (NHLBI) at NIH. Upon completion of her fellowship, she continued her work with the Genitourinary Malignancies Branch at the NCI as a Staff Clinician. Dr. Karzai is board certified in medical oncology and internal medicine.